The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension
Open accessAbstract
BACKGROUND: Scleroderma-associated pulmonary arterial hypertension (SSc-PAH) is a rare disease characterized by a very dismal response to therapy and poor survival. We assessed the effects of up-front combination PAH therapy in patients with SSc-PAH. METHODS: In this prospective, multicenter, open-label trial, 24 treatment-naive patients with SSc-PAH received ambrisentan 10 mg and tadalafil 40 mg daily for 36 weeks. Functional, hemodynamic, and imaging (cardiac magnetic resonance imaging and echocardiography) assessments at baseline and 36 weeks included changes in right ventricular (RV) mass and pulmonary vascular resistance as co-primary endpoints and stroke volume/pulmonary pulse pressure ratio, tricuspid annular plane systolic excursion, 6-minute walk distance, and N-terminal pro-brain natriuretic peptide as secondary endpoints. RESULTS: At 36 weeks, we found that treatment had resulted in significant reductions in median (interquartile range [IQR]) RV mass (28.0 g [IQR, 20.6-32.9] vs. 32.5 g [IQR, 23.2-41.4]; P < 0.05) and median pulmonary vascular resistance (3.1 Wood units [IQR, 2.0-5.7] vs. 6.9 Wood units [IQR, 4.0-12.9]; P < 0.0001) and in improvements in median stroke volume/pulmonary pulse pressure ratio (2.6 ml/mm Hg [IQR, 1.8-3.5] vs. 1.4 ml/mm Hg [IQR 8.9-2.4]; P < 0.0001) and mean ( ± SD) tricuspid annular plane systolic excursion (2.2 ± 0.12 cm vs. 1.65 ± 0.11 cm; P < 0.0001), 6-minute walk distance (395 ± 99 m vs. 343 ± 131 m; P = 0.001), and serum N-terminal pro-brain natriuretic peptide (647 ± 1,127 pg/ml vs. 1,578 ± 2,647 pg/ml; P < 0.05). CONCLUSIONS: Up-front combination therapy with ambrisentan and tadalafil significantly improved hemodynamics, RV structure and function, and functional status in treatment-naive patients with SSc-PAH and may represent a very effective therapy for this patient population. In addition, we identified novel hemodynamic and imaging biomarkers that could have potential value in future clinical trials. Clinical trial registered with www.clinicaltrials.gov (NCT01042158).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Updated clinical classification of pulmonary hypertension
Simonneau, G., Gatzoulis, M. A., Adatia, I., Celermajer, D., Denton, C., Ghofrani, A., Gomez Sanchez, M. A., Krishna Kumar, R., Landzberg, M., Machado, R. F., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.029 · Cited by 4,191
van de Veerdonk, M. C., Kind, T., Marcus, J. T., Mauritz, G.-J., Heymans, M. W., Bogaard, H.-J., Boonstra, A., Marques, K. M. J., Westerhof, N., & Vonk-Noordegraaf, A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.068 · Cited by 846
Cited by
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
Self-citation2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Risk stratification and medical therapy of pulmonary arterial hypertension
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01889-2018 · Cited by 819
Pulmonary veno-occlusive disease
Montani, D., Lau, E. M., Dorfmüller, P., Girerd, B., Jaïs, X., Savale, L., Perros, F., Nossent, E., Garcia, G., Parent, F., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2016 · Cited by 517
Epidemiology and treatment of pulmonary arterial hypertension
Lau, E. M. T., Giannoulatou, E., Celermajer, D. S., & Humbert, M. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.84 · Cited by 507
Metadata
- Authors
- Hassoun, P. M., Zamanian, R. T., Damico, R., Lechtzin, N., Khair, R., Kolb, T. M., Tedford, R. J., Hulme, O. L., Housten, T., Pisanello, C., Sato, T., Pullins, E. H., Corona-Villalobos, C. P., Zimmerman, S. L., Gashouta, M. A., Minai, O. A., Torres, F., Girgis, R. E., Chin, K., & Mathai, S. C.
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-11-01
- Volume
- 192
- Issue
- 9
- Pages
- 1102-1110
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- OpenAlex
- W1936073859
- Cited by
- 172
- References
- 2
- FWCI
- 14.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. https://app.cochat.ai/papers/10.1164/rccm.201507-1398oc
- The paper
- Hassoun, P. M., Zamanian, R. T., Damico, R., Lechtzin, N., Khair, R., Kolb, T. M., Tedford, R. J., Hulme, O. L., Housten, T., Pisanello, C., Sato, T., Pullins, E. H., Corona-Villalobos, C. P., Zimmerman, S. L., Gashouta, M. A., Minai, O. A., Torres, F., Girgis, R. E., Chin, K., & Mathai, S. C. (2015). Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201507-1398oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.